A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia.
نویسندگان
چکیده
We performed a double-blind cross-over study with amantadine hydrochloride in 12 patients with Friedreich's disease and 2 with autosomal dominant cerebellar ataxia. Patients were randomly assigned to a placebo-amantadine or amantadine-placebo sequence. The interval between the treatments was two weeks. Patients were graded according to a functional ataxia scoring scale and videotaped in basal conditions and 90 min after a single oral dose of 100 mg amantadine or placebo. Three evaluators independently scored the videotapes. Statistical analysis showed no significant effect of amantadine in Friedreich's disease.
منابع مشابه
Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study.
OBJECTIVE A group of 27 patients with Friedreich's ataxia and another group of 30 patients with olivopontocerebellar atrophies were each randomly divided into two subgroups, one receiving placebo and the other amantadine hydrochloride (AH; 200 mg daily) for three to four months. METHODS The effect of double blind treatment was evaluated by simple visual and auditory reaction time (RT) and mov...
متن کاملTherapeutic Effect of Co-Administration of Amantadine and Aspirin on Fatigue in Patients with Multiple Sclerosis: A Randomized Placebo-Controlled Double-Blind Study
Fatigue is recognized as one of the most disabling and frequent symptoms of multiple sclerosis (MS). Amantadine appears to have some proven ability to alleviate the fatigue in MS. The aim of this study was to assess the efficacy of co-administration of amantadine and aspirin for the treatment of fatigue in multiple sclerosis. Forty-five ambulatory patients aged 20–50 years with a diagnosis of M...
متن کاملAmantadine therapy for fatigue in multiple sclerosis.
We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo. On amantadine 31% had marked improvement; 15.6% moderate improvement; 15.6% mild improvement; and 36.5% unchanged. On placebo, none noted marked improvement; one claimed moderate improvement on either amantadine or placebo. 18.7% repor...
متن کاملIntravenous Amantadine for Freezing of Gait Resistant to Dopaminergic Therapy: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Clinical Trial
BACKGROUND Freezing of gait (FOG) is one of the most disabling symptoms in Parkinsonism. Open-label studies have suggested that intravenous (IV) amantadine is effective against FOG resistant to dopaminergic therapy in Parkinson's disease (PD). We evaluated the efficacy of IV amantadine on FOG resistant to dopaminergic therapy. METHODOLOGY/PRINCIPAL FINDINGS This was a randomized, double-blind...
متن کاملPreliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia
BACKGROUND AND PURPOSE Multiple system atrophy with predominant cerebellar ataxia is a disabling neurologic disease. However, effective management has not yet been established. We conducted a short-term, open-label preliminary study to assess the benefits of intravenous amantadine treatment in patients with probable multiple system atrophy with predominant cerebellar ataxia. METHODS Twenty pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
دوره 20 1 شماره
صفحات -
تاریخ انتشار 1993